{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T06:37:46Z","timestamp":1757313466228,"version":"3.40.5"},"reference-count":49,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"unspecified","delay-in-days":59,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Trans. Sci."],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:sec id=\"S2059866122003727_as1\">\n\t    <jats:title>Introduction:<\/jats:title>\n\t    <jats:p>This research examined the perspective of the Huntington\u2019s disease (HD) community regarding the use of predictive biomarkers as endpoints for regulatory approval of therapeutics to prevent or delay the onset of clinical HD in asymptomatic mutation carriers.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2059866122003727_as2\">\n\t    <jats:title>Methods:<\/jats:title>\n\t    <jats:p>An online, choice-based conjoint survey was shared with HD community members including untested at-risk individuals, presymptomatic mutation carriers, and symptomatic individuals. Across 15 scenarios, participants chose among two proposed therapies with differing degrees of biomarker improvement and side effects or a third option of no treatment.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2059866122003727_as3\">\n\t    <jats:title>Results:<\/jats:title>\n\t    <jats:p>Two hundred and thirty-eight responses were received. Attributes reflecting biomarker efficacy (e.g., prevention of brain atrophy on magnetic resonance imaging, reduced mutant huntingtin, or reduced inflammation biomarkers) had 3- to 7-fold greater importance than attributes representing side effects (e.g., increased risk of heart disease, cancer, and stroke over 20 years) and were more influential in directing choice of treatments. Reduction in mutant huntingtin protein was the most valued attribute overall. Multinomial logit model simulations based on survey responses demonstrated high interest among respondents (87\u201399% of the population) for drugs that might prevent or delay HD solely based upon biomarker evidence, even at the risk of serious side effects.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S2059866122003727_as4\">\n\t    <jats:title>Conclusion:<\/jats:title>\n\t    <jats:p>These results indicate a strong desire among members of the HD community for preventive therapeutics and a willingness to accept significant side effects, even before the drug has been shown to definitively delay disease onset if the drug improves biomarker evidence of HD progression. Preferences of the HD community should inform regulatory policies for approving preventive therapies.<\/jats:p>\n\t  <\/jats:sec>","DOI":"10.1017\/cts.2022.372","type":"journal-article","created":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T11:01:31Z","timestamp":1646132491000},"source":"Crossref","is-referenced-by-count":1,"title":["Preventive drugs for Huntington\u2019s disease: A choice-based conjoint survey of patient preferences"],"prefix":"10.1017","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7487-426X","authenticated-orcid":false,"given":"Marcus C.","family":"Parrish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Hanson-Kahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin V.","family":"Grimes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2022,3,1]]},"reference":[{"key":"S2059866122003727_ref13","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2010.208264"},{"key":"S2059866122003727_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30124-2"},{"key":"S2059866122003727_ref10","doi-asserted-by":"publisher","DOI":"10.3233\/JHD-160213"},{"key":"S2059866122003727_ref7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005005"},{"key":"S2059866122003727_ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2014.00078"},{"key":"S2059866122003727_ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.5"},{"key":"S2059866122003727_ref19","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.712555"},{"key":"S2059866122003727_ref27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187709"},{"key":"S2059866122003727_ref38","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11080815"},{"key":"S2059866122003727_ref42","doi-asserted-by":"publisher","DOI":"10.1037\/a0013608"},{"key":"S2059866122003727_ref29","doi-asserted-by":"publisher","DOI":"10.2165\/11539650-000000000-00000"},{"key":"S2059866122003727_ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S0738-3991(98)00086-X"},{"key":"S2059866122003727_ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.03.022"},{"volume-title":"Getting Started with Conjoint Analysis: Strategies for Product Design and Pricing Research","year":"2005","author":"Orme","key":"S2059866122003727_ref25"},{"key":"S2059866122003727_ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-010-5768-0"},{"key":"S2059866122003727_ref18","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.558"},{"key":"S2059866122003727_ref32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163479"},{"key":"S2059866122003727_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30143-5"},{"key":"S2059866122003727_ref24","unstructured":"24. Patient-Focused Drug Development: Collecting Comprehensive and Representative Input - Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders, June 2020. (https:\/\/www.fda.gov\/media\/139088\/download)."},{"key":"S2059866122003727_ref26","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2016-039"},{"key":"S2059866122003727_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2019.02.004"},{"key":"S2059866122003727_ref47","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27653"},{"key":"S2059866122003727_ref21","unstructured":"21. Center for Drug Evaluation and Research. Accelerated approval program. U.S. Food and Drug Administration, October 26, 2020. (https:\/\/www.fda.gov\/drugs\/information-health-care-professionals-drugs\/accelerated-approval-program)."},{"key":"S2059866122003727_ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-016-0598-4"},{"key":"S2059866122003727_ref9","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20080178"},{"key":"S2059866122003727_ref15","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.24"},{"key":"S2059866122003727_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2010.04.003"},{"key":"S2059866122003727_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2014.09.011"},{"key":"S2059866122003727_ref23","unstructured":"23. Early alzheimer\u2019s disease: Developing drugs for treatment - Guidance for Industry. U.S. FDA Center for Drug Evaluation and Research, February 2018. (https:\/\/www.fda.gov\/files\/drugs\/published\/Alzheimer%E2%80%99s-Disease---Developing-Drugs-for-Treatment-Guidance-for-Industy.pdf)."},{"key":"S2059866122003727_ref45","doi-asserted-by":"publisher","DOI":"10.1177\/0091415018784737"},{"key":"S2059866122003727_ref49","doi-asserted-by":"publisher","DOI":"10.3233\/ADR-200214"},{"key":"S2059866122003727_ref44","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e318181e4c7"},{"key":"S2059866122003727_ref41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.8077"},{"key":"S2059866122003727_ref48","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.14364"},{"key":"S2059866122003727_ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2008.00068.x"},{"key":"S2059866122003727_ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0004.2004.00241.x"},{"key":"S2059866122003727_ref6","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat7108"},{"key":"S2059866122003727_ref22","unstructured":"22. Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment - Guidance for Industry. U.S. FDA Center for Drug Evaluation and Research, September 2019. (https:\/\/www.fda.gov\/media\/130964\/download)."},{"key":"S2059866122003727_ref33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172762"},{"key":"S2059866122003727_ref30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002636"},{"key":"S2059866122003727_ref34","article-title":"Hierachical Bayes: why all the attention?","author":"Orme","year":"2000","journal-title":"Quirk\u2019s Marketing Research Review"},{"key":"S2059866122003727_ref37","unstructured":"37. The Voice of the Patient: Huntington\u2019s Disease. U.S. FDA Center for Drug Evaluation and Research, 2016. (https:\/\/www.fda.gov\/files\/about%20fda\/published\/The-Voice-of-the-Patient--Huntington%E2%80%99s-Disease.pdf)."},{"key":"S2059866122003727_ref40","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130548"},{"key":"S2059866122003727_ref14","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A2018"},{"key":"S2059866122003727_ref46","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-200106"},{"key":"S2059866122003727_ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s10897-013-9627-x"},{"key":"S2059866122003727_ref31","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.13719"},{"key":"S2059866122003727_ref36","doi-asserted-by":"publisher","DOI":"10.2196\/jmir.7071"},{"key":"S2059866122003727_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70088-7"}],"container-title":["Journal of Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2059866122003727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T10:14:47Z","timestamp":1649326487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2059866122003727\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022]]}},"alternative-id":["S2059866122003727"],"URL":"https:\/\/doi.org\/10.1017\/cts.2022.372","relation":{},"ISSN":["2059-8661"],"issn-type":[{"type":"electronic","value":"2059-8661"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"e35"}}